Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Invested Capital (2016 - 2026)

Myriad Genetics has reported Invested Capital over the past 16 years, most recently at $487.9 million for Q4 2025.

  • Quarterly Invested Capital fell 34.13% to $487.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $487.9 million through Dec 2025, down 34.13% year-over-year, with the annual reading at $487.9 million for FY2025, 34.13% down from the prior year.
  • Invested Capital was $487.9 million for Q4 2025 at Myriad Genetics, down from $492.3 million in the prior quarter.
  • Over five years, Invested Capital peaked at $1.0 billion in Q1 2021 and troughed at $447.5 million in Q2 2025.
  • The 5-year median for Invested Capital is $810.8 million (2023), against an average of $803.6 million.
  • Year-over-year, Invested Capital increased 6.68% in 2024 and then crashed 42.66% in 2025.
  • A 5-year view of Invested Capital shows it stood at $967.8 million in 2021, then decreased by 8.47% to $885.8 million in 2022, then fell by 7.24% to $821.7 million in 2023, then fell by 9.86% to $740.7 million in 2024, then crashed by 34.13% to $487.9 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Invested Capital are $487.9 million (Q4 2025), $492.3 million (Q3 2025), and $447.5 million (Q2 2025).